In this issue of Insights, we summarize a recent discussion held with a number of pharmaceutical companies on US health policy, potential priorities for the Trump administration, and yes, pricing. Tim Wilsdon, an expert in international policy issues affecting the development and commercialization of medicines, led the discussion.
To read more, click the link below.
Busting a myth: Is achieving US drug prices in Europe impossible?
To answer this question, the authors searched for evidence in the individual countries. Germany and the UK, for example, are the two European countries where...